Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

14 evidence topics · 8 sources

Summary

The 2026 international guideline sequences treatment as a standard-dose second-generation H1-antihistamine first line, updosing up to 4-fold second line, then add-on omalizumab (recommended), dupilumab, or remibrutinib (both suggested) for CSU unresponsive to high-dose antihistamines, and off-label ciclosporin for CU unresponsive to licensed treatments. The guideline states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges cost restrictions on the three advanced therapies, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A US Joint Task Force guideline that addresses the sequencing of conventional and advanced therapies was in draft for member review in 2026; the network meta-analysis commissioned for it rated standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib among the most effective with high certainty. In a primary care pathway, patients who remain symptomatic and adherent after up to four times the standard antihistamine dose should be referred for specialist evaluation, where total IgE and IgG-anti-TPO may be tested to indicate the likelihood of response to omalizumab. The barzolvolimab phase 3 trials, which study adults with CSU who remain symptomatic despite H1 antihistamine treatment, enrolled 1,939 participants, including advanced therapy-experienced or refractory participants, and are designed to detect a difference in an omalizumab-refractory subpopulation. The manufacturer describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.” It is supplied for the trials in 1 mL pre-filled syringes for subcutaneous injection, which the manufacturer states allows potential self-administration at home.

International guideline treatment algorithm: antihistamines, then omalizumab, dupilumab, or remibrutinib, then ciclosporin

“We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend updosing of a 2nd generation H1-antihistamine up to 4-fold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamines as second-line treatment before other treatments are considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend adding on omalizumab* for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest using dupilumab* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest using remibrutinib* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest using ciclosporin* for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Network meta-analysis commissioned for the draft US guideline: comparative effectiveness of systemic treatments